Back to Search Start Over

Tolerability of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy subjects.

Authors :
Chaudhry V
Giuliani M
Petty BG
Lee D
Seyedsadr M
Hilt D
Cornblath DR
Source :
Muscle & nerve [Muscle Nerve] 2000 Feb; Vol. 23 (2), pp. 189-92.
Publication Year :
2000

Abstract

This phase I, double-blind, randomized, placebo-controlled study evaluated the safety of single and multiple (daily for 7 days) subcutaneous administrations of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy human volunteers at seven doses, ranging from 3 to 500 microg/kg/day. No serious or life-threatening adverse events occurred. The most frequently recorded adverse effects were mild injection-site pain, diarrhea, and elevation of liver function tests. No change in neurologic function was noted with these dosing regimens. We conclude that r-metHuNT3 is safe and well tolerated in the dosages used in this study.<br /> (Copyright 2000 John Wiley & Sons, Inc.)

Details

Language :
English
ISSN :
0148-639X
Volume :
23
Issue :
2
Database :
MEDLINE
Journal :
Muscle & nerve
Publication Type :
Academic Journal
Accession number :
10639609
Full Text :
https://doi.org/10.1002/(sici)1097-4598(200002)23:2<189::aid-mus7>3.0.co;2-8